Edition:
United Kingdom

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

39.63USD
23 May 2018
Change (% chg)

$0.42 (+1.07%)
Prev Close
$39.21
Open
$38.97
Day's High
$39.70
Day's Low
$38.88
Volume
1,292,971
Avg. Vol
1,627,030
52-wk High
$47.81
52-wk Low
$29.44

Latest Key Developments (Source: Significant Developments)

Mylan Adds To Growing Women's Healthcare Portfolio With Launch Of Generic For Oral Contraceptive Yaz
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Mylan NV ::MYLAN ADDS TO GROWING WOMEN'S HEALTHCARE PORTFOLIO WITH LAUNCH OF GENERIC FOR ORAL CONTRACEPTIVE YAZ®.MYLAN NV - U.S. LAUNCH OF DROSPIRENONE AND ETHINYL ESTRADIOL TABLETS USP, 3 MG/0.02 MG, A GENERIC VERSION OF BAYER'S YAZ TABLETS.  Full Article

Generic-drug companies face first charges in U.S. probe - Bloomberg
Tuesday, 24 Apr 2018 

April 24 (Reuters) - :GENERIC-DRUG COMPANIES FACE FIRST CHARGES IN U.S. PROBE - BLOOMBERG, CITING SOURCES.AT LEAST TWO COMPANIES ARE ON TRACK TO BE INDICTED IN THE COMING MONTHS, IN ADDITION TO SEVERAL EXECUTIVES - BLOOMBERG, CITING SOURCES .  Full Article

Mylan Acquires Global Development & Marketing Rights For Meloxicam
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Mylan NV ::MYLAN - ACQUIRED GLOBAL DEVELOPMENT & MARKETING RIGHTS FROM PRAYOG LABS TO BRING TO MARKET FAST-ACTING MELOXICAM AS PROPOSED NON-NARCOTIC ANALGESIC.MYLAN SAYS WILL BE SUBMITTING AN INVESTIGATIONAL NEW DRUG APPLICATION TO U.S. FDA FOR MELOXICAM.  Full Article

Mylan Partners With Fujifilm Kyowa Kirin Biologics
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Mylan NV ::MYLAN PARTNERS WITH FUJIFILM KYOWA KIRIN BIOLOGICS TO COMMERCIALIZE BIOSIMILAR TO HUMIRA® (ADALIMUMAB).MYLAN NV - COMPANIES EXPECT TO RECEIVE A DECISION FROM EMA IN SECOND HALF OF 2018.MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS GRANTS MYLAN AN EXCLUSIVE LICENSE TO COMMERCIALIZE ADALIMUMAB BIOSIMILAR IN EUROPE.MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS IS ELIGIBLE TO RECEIVE A SUBSEQUENT COMMERCIALIZATION MILESTONE PAYMENT AND SALES ROYALTIES.MYLAN NV - FUJIFILM KYOWA KIRIN BIOLOGICS WILL RECEIVE AN UP-FRONT FEE UNDER DEAL.MYLAN NV -CO, FUJIFILM KYOWA KIRIN BIOLOGICS CONTINUE TO NEGOTIATE FOR COMMERCIALIZING PRODUCT IN ADDITIONAL TERRITORIES.MYLAN NV - UNDER AGREEMENT TERMS CO TO BE RESPONSIBLE FOR SALES ACTIVITY OF PRODUCT IN EUROPEAN COUNTRIES.MYLAN NV - CO, FUJIFILM KYOWA KIRIN BIOLOGICS EXPECT TO RECEIVE DECISION FROM EMA REGARDING MAA FOR PROPOSED BIOSIMILAR TO HUMIRA IN H2 2018.  Full Article

Mylan Extends Debt Maturities With $1.5 Billion Bond Offering
Friday, 6 Apr 2018 

April 6 (Reuters) - Mylan NV ::MYLAN STRENGTHENS ITS CAPITAL STRUCTURE BY EXTENDING ITS DEBT MATURITIES WITH A SUCCESSFUL $1.5 BILLION BOND OFFERING.MYLAN NV - ‍PRICING OF A PRIVATE OFFERING OF $1.5 BLN AGGREGATE PRINCIPAL AMOUNT OF SENIOR NOTES ON MARCH 28, 2018​​.MYLAN NV - ‍NOTES WILL BE ISSUED BY MYLAN INC. AND GUARANTEED BY MYLAN N.V.​​.MYLAN NV - ALSO INTENDS TO REPAY EUR 500 MLN AGGREGATE PRINCIPAL AMOUNT OF NOTES DUE IN NOVEMBER 2018 AT MATURITY.MYLAN NV - OFFERING COMPRISED OF ‍$750 MLN OF 4.550% SENIOR NOTES DUE 2028, $750 MLN OF 5.200% SENIOR NOTES DUE 2048​​.  Full Article

Mylan Introduces Symfi Triple Combo Once-Daily HIV Treatment In The U.S.
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Mylan Nv ::MYLAN INTRODUCES SYMFI™ TRIPLE COMBO ONCE-DAILY HIV TREATMENT IN THE U.S..MYLAN NV - INTRODUCE IN U.S. THIRD COST-SAVING HIV COMBINATION.  Full Article

Mylan To Complete $1 Billion Share Repurchase Plan
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Mylan Nv ::MYLAN TO COMPLETE $1 BILLION SHARE REPURCHASE PLAN.MYLAN - AS PER AGREEMENT WITH ABBOTT RELATED TO ABBOTT EPD DEAL, ABBOTT NOTIFIED MYLAN IT SOLD REMAINING 20.3 MILLION IN MYLAN SHARES PRIOR TO YEAR-END​.  Full Article

Mylan Announces FDA Approval Of First Generic For Estrace Cream
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Mylan Nv ::MYLAN ADDS TO U.S. WOMEN'S HEALTHCARE PORTFOLIO WITH FDA APPROVAL OF FIRST GENERIC FOR ESTRACE® CREAM.MYLAN NV- ANNOUNCED U.S. LAUNCH OF ESTRADIOL VAGINAL CREAM USP, 0.01%, FIRST GENERIC VERSION OF ALLERGAN'S ESTRACE CREAM.  Full Article

Biocon And Mylan's Biosimilar Trastuzumab Gets Approval From ANVISA, Brazil
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Biocon Ltd ::CO AND MYLAN'S BIOSIMILAR TRASTUZUMAB RECEIVES APPROVAL FROM ANVISA, BRAZIL THROUGH THEIR PARTNER LIBBS.LIBBS FARMACEUTICA TO COMMERCIALIZE PRODUCT IN BRAZIL UNDER BRAND NAME ZEDORA.  Full Article

Mylan Announces U.S. Regulator's Review Proceedings On All Claims Against Sanofi's Lantus Patents
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Mylan Nv ::MYLAN ANNOUNCES THE U.S. PATENT AND TRADEMARK APPEAL BOARD INSTITUTES INTER PARTES REVIEW PROCEEDINGS ON ALL CLAIMS AGAINST SANOFI'S LANTUS® PATENTS.MYLAN SAYS U.S. PTAB INSTITUTED IPR PROCEEDINGS ON CLAIMS AGAINST 2 ORANGE BOOK-LISTED PATENTS OWNED BY SANOFI FOR LANTUS 100 UNITS/ML.  Full Article

Photo

GSK bets on lift from new lung drugs ahead of Advair's last gasp

LONDON GlaxoSmithKline is putting more marketing muscle behind its new lung drugs and is looking for a sales boost as top respiratory experts gather to analyse clinical trials data at a meeting in San Diego this weekend.